¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023 Çѱ¹ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ Ãá°èÇмú´ëȸ (2023 SoLA of KSoLA) : 2023-04-01

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2023 Çѱ¹ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ Ãá°èÇмú´ëȸ (2023 SoLA of KSoLA) : 2023-04-01
±³À°ÀÏÀÚ : 2023-04-01
±³À°Àå¼Ò : ¼­¿ïµå·¡°ï½ÃƼ ÄÁº¥¼Ç¼¾ÅÍ 3Ãþ ÇѶóȦ

±³À°ÁÖÁ¦ : 2023 Çѱ¹ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ Ãá°èÇмú´ëȸ (2023 SoLA of KSoLA)

ÁÖÃÖ±â°ü : Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ
´ã´çÀÚ : 2023 SoLA Áغñ»ç¹«±¹
¿¬¶ôó : 02-6734-1011  

À̸ÞÀÏ : sola2023@planbear.co.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 12 ½Ã°£ 30ºÐ

¼¼ºÎ¼ö°­·á : 70,000¿ø  

ºñ°í ±³¼ö, °³¿øÀÇ, ºÀÁ÷ÀÇ È¸¿ø »çÀüµî·Ï 40,000¿ø/ÇöÀåµî·Ï 50,000¿ø,ºñȸ¿ø »çÀüµî·Ï 60,000¿ø/ ÇöÀåµî·Ï 70,000¿øÀüÀÓÀÇ, ¿µ¾ç»ç, ¿îµ¿»ç, °£È£»ç, ¿¬±¸¿ø ¹× ±âŸ Âü°¡ÀÚȸ¿ø »çÀüµî·Ï 20,000¿ø/ÇöÀåµî·Ï 30,000¿øºñȸ¿ø »çÀüµî·Ï 40,000¿ø/ÇöÀåµî·Ï 50,000¿ø Àü°øÀÇ, Çлý, ±ºÀÇ°ü, °øÁߺ¸°ÇÀÇ, 65¼¼ ÀÌ»ó ¹«·á


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 04-01 ÇѶóȦ Room2 07:30~08:30 Combination therapy of ezetimibe and atorvastatin for dyslipidemia ±èÇý°æ(¿¬¼¼ÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 08:30~08:50 Triglyceride lowering with pemafibrate to reduce cardiovascular risk ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 08:50~09:10 Lipoprotein(a) reduction in persons with cardiovascular disease ÀÌÀºÁ¤(¼º±Õ°üÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 09:10~09:30 A comparison of two LDL cholesterol targets after Ischemic stroke ±è¹üÁØ(¿ï»êÀÇ´ë ½Å°æ°ú)

Åä·Ð 04-01 ÇѶóȦ Room1 09:30~10:00 Panel discussion ()

ÈÞ½Ä 04-01 ÇѶóȦ Room1 10:00~10:15 Break ()

±âŸ 04-01 ÇѶóȦ Room1 10:15~10:20 Opening address ()

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 10:20~11:00 Past and prospect of atherosclerosis therapy ÀÌ»óÇÐ(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú)

ÈÞ½Ä 04-01 ÇѶóȦ Room1 11:00~12:00 Coffee break & Poster viewing ()

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 12:00~13:00 Cutting edge care of pitavastatin with ezetimibe combination therapy È«ÁØÈ­(À»ÁöÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room2 12:00~13:00 Atorvastatin/Ezetimibe treatment for the dyslipidemia in diabetic patients ÀÌ¿ëÈ£(¿¬¼¼ÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 13:00~13:20 Pros À̼ö¿ë(ºÎ»êÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 13:20~13:40 Cons ÇѼº¸²(¼­¿ï´ë ½ÄÇ°¿µ¾çÇаú)

Åä·Ð 04-01 ÇѶóȦ Room1 13:40~13:50 Rebuttal ()

Åä·Ð 04-01 ÇѶóȦ Room1 13:50~14:30 Panel discussion ()

±³À°½Ã°£ 04-01 ÇѶóȦ Room2 13:00~13:20 A potential therapeutic target for atherosclerotic calcification ÃÖÀçÈÆ(ÇѾç´ë »ý¸í°úÇаú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room2 13:20~13:40 Vasoprotective role of angiogenic adipokine ÇÏâÈÆ(¿ï»êÀÇ´ë À¶ÇÕÀÇÇаú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room2 13:40~13:50 A novel pathway to prevent VSMC proliferation in neointimal hyperplasia ±èÀ±ÇÐ(ºÎ»ê´ë ÇغÎÇб³½Ç)

Åä·Ð 04-01 ÇѶóȦ Room2 13:50~14:30 Panel discussion ()

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 14:30~14:50 New, novel lipid-lowering agents for reducing cardiovascular risk: beyond statins ÃÖ¼ºÈñ(¼­¿ïÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 14:50~15:10 Anti-Inflammatory therapy for cardiovascular disease À±Á¾Âù(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 15:10~15:30 wincretin (GLP-1/GIP dual agonist) for type 2 diabetes and obesity Á¤Ã¢Èñ(¿ï»êÀÇ´ë ³»ºÐºñ³»°ú)

Åä·Ð 04-01 ÇѶóȦ Room1 15:30~16:00 Panel discussion ()

±³À°½Ã°£ 04-01 ÇѶóȦ Room2 14:30~14:50 CV Risk assessment for lipid guidelines: current status & future perspective ÀÌÈ£±Ô(¿¬¼¼ÀÇ´ë ¿¹¹æÀÇÇб³½Ç)

±³À°½Ã°£ 04-01 ÇѶóȦ Room2 14:50~15:10 Emerging risk factors & biomarkers as CV risk enhancers ÀÌ´Ù¿µ(°í´ëÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room2 15:10~15:30 Coronary artery calcium score for CV risk reclassification ¿ÀÁø°æ(Ãæ³²ÀÇ´ë ½ÉÀå³»°ú)

Åä·Ð 04-01 ÇѶóȦ Room2 15:30~16:00 Panel discussion ()

ÈÞ½Ä 04-01 ÇѶóȦ Room1 16:00~16:20 Coffee break ()

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 16:20~16:40 Pros Á¤¿µÈÆ(Áß¾ÓÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 16:40~17:00 Cons ±è½Å°ï(°í·ÁÀÇ´ë ³»ºÐºñ³»°ú)

Åä·Ð 04-01 ÇѶóȦ Room1 17:00~17:10 Rebuttal ()

Åä·Ð 04-01 ÇѶóȦ Room1 17:10~17:40 Panel discussion ()

±âŸ 04-01 ÇѶóȦ Room1 17:40~17:50 Closing remark ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023 Çѱ¹ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ Ãá°èÇмú´ëȸ (2023 SoLA of KSoLA) : 2023-04-01""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÀÓ»ó³ëÀÎÀÇÇÐȸ 2023 Ãá°è ³ëÀÎÀÇÇÐ ¿¬¼ö°­Á : 2023-04-02
´ÙÀ½±Û Áß¾Ó´ëÇб³º´¿ø Á¤½Å°Ç°­ÀÇÇаú 2023 Ãá°è¿¬¼ö±³À° ¡°¸ð¼º°ú Á¤½Å°Ç°­¡± : 2023-04-01
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 56 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 38 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 39 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 51 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 40 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 37 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 13 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 14 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 33 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 16 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 15 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 36 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 26 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 31 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 24 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷